Participants that completed a qualifying study through Week 52.
You may not be if
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation.
Previous administration with an investigational product (drug or vaccine) other than dazukibart in a qualifying study within 30 days (or as determined by the local requirement) or 5 half-lives preceding baseline in this study (whichever is longer).
Current use of any prohibited concomitant medication(s).
Active bacterial, viral, fungal, mycobacterial or other infections.
Ongoing adverse event in a qualifying study or the participant has met safety monitoring criteria in a qualifying study that have not resolved.
Investigator site staff or sponsor employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Clareo Health | A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
